Immunomodulatory Therapy (IMT) is essential in ophthalmology for treating autoimmune and inflammatory eye diseases such as uveitis, scleritis, and ocular cicatricial pemphigoid. IMT works by adjusting the immune system to lessen inflammation and prevent eye tissue damage, which is crucial for maintaining vision. The therapy often involves the use of corticosteroids, antimetabolites, T-cell inhibitors, and biologics. These treatments aim to induce long-term remission and reduce dependency on corticosteroids, thereby mitigating risks of steroid-related complications like glaucoma and cataracts. Tailored treatment plans based on the severity of the condition and individual patient needs are vital for achieving optimal results and improving the quality of life for those with chronic ocular inflammatory disorders.
Aims: This comprehensive review aims to evaluate the mechanism, long-term safety, efficacy, and disease-specific applications of tumour necrosis factor-alpha (TNF-α) inhibitors in the treatment of…
Sessions are CPD-accredited by The CPD Group (UK) — one CPD credit for every hour of attendance.
Oral and poster slots for original Immunomodulatory Therapy work, reviewed by the scientific committee.
Meet ophthalmologists, vision scientists, and eye-care clinicians from around the world across three days.
Accepted abstracts are compiled into the conference proceedings and indexed in Scopus and Web of Science.
Plenary lectures from leading voices shaping Immunomodulatory Therapy research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Immunomodulatory Therapy track is a dedicated stream within IOC 2027 covering the latest research, clinical innovation, and best practice in Immunomodulatory Therapy. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Ophthalmologists, optometrists, vision scientists, educators, doctoral students, and trainees with an interest in Immunomodulatory Therapy are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IOC 2027 is a hybrid conference — attend the Immunomodulatory Therapy track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
